FTAI Aviation Ltd vs Zimmer Biomet Holdings Inc — how do they compare? FTAI Aviation Ltd trades at $199.72 (market cap $21.93B), while Zimmer Biomet Holdings Inc trades at $92.9 (market cap $17.44B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| FTAI | ZBH | |
|---|---|---|
Market Cap | $21.93B | $17.44B |
Sector | Industrials | Health |
52-Week High | $310.04 | $107.71 |
52-Week Low | $109.92 | $79.58 |
Enterprise Value | $24.97B | $24.49B |
Dividend Yield | 0.7% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $205.71, down 0.25% with a bearish technical outlook despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51 billion in 2025 with 19% net margins, though recent quarters show earnings misses. Positive developments include a strategic Boeing 737-800 freighter collaboration and expansion into data center power solutions, while negative operating cash flow raises execution concerns.
The stock presents growth potential from aerospace servicing and new power segment opportunities, but faces risks from consistent earnings misses and high valuations (P/E 42.6). Institutional sentiment remains strongly positive with 100% buy ratings, though technical indicators suggest near-term pressure with support at $195.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →